The weekly litigation news digest is live. Subscribe now
Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations - EP4025188
The patent EP4025188 was granted to Janssen Pharmaceutica on Jan 10, 2024. The application was originally filed on May 7, 2021 under application number EP21724652A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP4025188
- Application Number
- EP21724652A
- Filing Date
- May 7, 2021
- Status
- Granted And Under Opposition
- Dec 8, 2023
- Publication Date
- Jan 10, 2024
- External Links
- Slate, Register, Google Patents
Patent Summary
Paliperidone palmitate for treating psychosis, schizophrenia, schizoaffective disorder, and bipolar disorder through a novel dosing strategy that enables continuous treatment with once-monthly injections. The dosing regimen involves administering a re-initiation loading dose of the extended-release formulation after a minimum six-month gap from the initial injection, followed by maintenance doses. This approach addresses the common challenge of medication adherence by providing a continuous therapeutic effect while minimizing the need for frequent clinic visits.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (16) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents